Beam Therapeutics BEAM
Beam Therapeutics Inc. · Nasdaq · Biological Products, (No Diagnostic Substances)
$28.78+15.58%close on Oct. 28, 2026 · volume 5.0M · Yahoo Finance
Price, last 47 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 16, 2026 | John M. Evans CEO, director | Sold 10b5-1 plan | 25,000 | $23.98 | $599,595 |
| Oct. 15, 2026 | John M. Evans CEO, director | Sold 10b5-1 plan | 25,000 | $23.57 | $589,150 |
| Oct. 1, 2026 | Bethany J. Cavanagh SVP, Finance and Treasurer | Sold 10b5-1 plan | 187 | $24.41 | $4,565 |
| July 27, 2026 | Amy Simon Chief Medical Officer | Sold 10b5-1 plan | 16,667 | $25.74 | $429,037 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 8 →Results of operations and financial condition · Financial statements and exhibits